CHRS

Company Overview — What Does Coherus BioSciences, Inc. Do?

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus BioSciences, Inc. (CHRS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Denny M. Lanfear and employs approximately 330 people, headquartered in Redwood City, California. With a market capitalization of $261M, CHRS is one of the notable companies in the Healthcare sector.

Coherus BioSciences, Inc. (CHRS) Stock Rating — Reduce (April 2026)

As of April 2026, Coherus BioSciences, Inc. receives a Reduce rating with a composite score of 34.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CHRS ranks #2,652 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Coherus BioSciences, Inc. ranks #353 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CHRS Stock Price and 52-Week Range

Coherus BioSciences, Inc. (CHRS) currently trades at $1.64. The stock lost $0.01 (0.6%) in the most recent trading session. The 52-week high for CHRS is $2.62, which means the stock is currently trading -37.3% from its annual peak. The 52-week low is $0.71, putting the stock 131.0% above its annual trough. Recent trading volume was 557K shares, suggesting relatively thin trading activity.

Is CHRS Overvalued or Undervalued? — Valuation Analysis

Coherus BioSciences, Inc. (CHRS) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 1.28x, compared to the Healthcare sector average of 23.63x — a discount of 95%. The price-to-book ratio stands at 4.10x, versus the sector average of 2.75x. The price-to-sales ratio is 2.50x, compared to 1.66x for the average Healthcare stock.

At current multiples, Coherus BioSciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Coherus BioSciences, Inc. Profitability — ROE, Margins, and Quality Score

Coherus BioSciences, Inc. (CHRS) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 319.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 75.4% versus the sector average of -33.1%.

On a margin basis, Coherus BioSciences, Inc. reports gross margins of 67.6%, compared to 71.5% for the sector. The operating margin is -358.4% (sector: -66.1%). Net profit margin stands at 459.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -82.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CHRS Debt, Balance Sheet, and Financial Health

Coherus BioSciences, Inc. has a debt-to-equity ratio of 323.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.47x, suggesting adequate working capital coverage. Total debt on the balance sheet is $37M. Cash and equivalents stand at $103M.

CHRS has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in CHRS would be expected to move 43.2% more than the S&P 500 on any given day. The stability factor score for Coherus BioSciences, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Coherus BioSciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Coherus BioSciences, Inc. reported revenue of $100M and earnings per share (EPS) of $1.43. Net income for the quarter was $195M. Gross margin was 67.6%. Operating income came in at $-142M.

In FY 2025, Coherus BioSciences, Inc. reported revenue of $42M and earnings per share (EPS) of $1.43. Net income for the quarter was $168M. Gross margin was 67.2%. Revenue grew -84.2% year-over-year compared to FY 2024. Operating income came in at $-181M.

In Q3 2025, Coherus BioSciences, Inc. reported revenue of $12M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-36M. Gross margin was 67.8%. Revenue grew -83.7% year-over-year compared to Q3 2024. Operating income came in at $-44M.

In Q2 2025, Coherus BioSciences, Inc. reported revenue of $10M and earnings per share (EPS) of $2.57. Net income for the quarter was $298M. Gross margin was 66.9%. Revenue grew -84.2% year-over-year compared to Q2 2024. Operating income came in at $-45M.

Over the past 8 quarters, Coherus BioSciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $65M to $100M. Investors analyzing CHRS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CHRS Dividend Yield and Income Analysis

Coherus BioSciences, Inc. (CHRS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CHRS Momentum and Technical Analysis Profile

Coherus BioSciences, Inc. (CHRS) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

CHRS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Coherus BioSciences, Inc. (CHRS) ranks #353 out of 838 stocks based on the Blank Capital composite score. This places CHRS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CHRS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CHRS vs S&P 500 (SPY) comparison to assess how Coherus BioSciences, Inc. stacks up against the broader market across all factor dimensions.

CHRS Next Earnings Date

No upcoming earnings date has been announced for Coherus BioSciences, Inc. (CHRS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CHRS? — Investment Thesis Summary

The quantitative profile for Coherus BioSciences, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, Coherus BioSciences, Inc. (CHRS) earns a Reduce rating with a composite score of 34.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CHRS stock.

Related Resources for CHRS Investors

Explore more research and tools: CHRS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CHRS head-to-head with peers: CHRS vs AZN, CHRS vs SLGL, CHRS vs VMD.